DK0910647T3 - Human DNase i hyperaktive varianter - Google Patents

Human DNase i hyperaktive varianter

Info

Publication number
DK0910647T3
DK0910647T3 DK97929686T DK97929686T DK0910647T3 DK 0910647 T3 DK0910647 T3 DK 0910647T3 DK 97929686 T DK97929686 T DK 97929686T DK 97929686 T DK97929686 T DK 97929686T DK 0910647 T3 DK0910647 T3 DK 0910647T3
Authority
DK
Denmark
Prior art keywords
variants
human dnase
hyperactive
hyperactive variants
relates
Prior art date
Application number
DK97929686T
Other languages
English (en)
Inventor
Robert A Lazarus
Clark Qun Pan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0910647T3 publication Critical patent/DK0910647T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK97929686T 1996-06-14 1997-06-09 Human DNase i hyperaktive varianter DK0910647T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/663,831 US6391607B1 (en) 1996-06-14 1996-06-14 Human DNase I hyperactive variants
PCT/US1997/008517 WO1997047751A1 (en) 1996-06-14 1997-06-09 Human dnase i hyperactive variants

Publications (1)

Publication Number Publication Date
DK0910647T3 true DK0910647T3 (da) 2008-07-21

Family

ID=24663430

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97929686T DK0910647T3 (da) 1996-06-14 1997-06-09 Human DNase i hyperaktive varianter

Country Status (12)

Country Link
US (4) US6391607B1 (da)
EP (1) EP0910647B1 (da)
JP (1) JP3468778B2 (da)
AT (1) ATE389724T1 (da)
AU (1) AU737618B2 (da)
CA (1) CA2257133C (da)
DE (1) DE69738581T2 (da)
DK (1) DK0910647T3 (da)
ES (1) ES2301180T3 (da)
NZ (1) NZ333128A (da)
PT (1) PT910647E (da)
WO (1) WO1997047751A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
CN101195025A (zh) * 2001-03-15 2008-06-11 雷金纳克斯生物制药公司 胸腺素β4、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用
US7067298B2 (en) 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US20050016668A1 (en) * 2003-06-16 2005-01-27 Lori Powers Method and apparatus for cutting through an outer layer on a container
EP1666055A4 (en) * 2003-07-14 2010-02-10 Viktor Veniaminovich Tets METHOD OF TREATMENT OF ONCOLOGICAL, INFECTIOUS, AND SOMATIC DISEASES, METHODS OF MONITORING THE EFFICACY OF TREATMENT, AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF
RU2269358C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
JP2007532666A (ja) * 2004-04-14 2007-11-15 アヴィリッド インコーポレーテッド ウイルス核酸を対象とした修飾ヌクレアーゼを用いた組成物及びウイルス性疾患の予防並びに治療方法
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
US20080044851A1 (en) * 2006-06-02 2008-02-21 Epicentre Technologies Compositions and methods for removal of DNA from a sample
BRPI0717439A2 (pt) 2006-10-18 2013-11-19 Periness Ltd Composição farmacêutica, e, métodos para tratar subfertilidade masculina, para determinar um estado de fertlidade em um indivíduo do sexo masculino, para a reprodução assistida, para selecionar uma técnica de reprodução assistida e para selecionar células de esperma em uma população de células de esperma para uso em uma técnica de reprodução auxiliada.
PL2095825T3 (pl) * 2006-11-28 2011-12-30 Cls Therapeutics Ltd Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu
US8535925B2 (en) 2009-04-10 2013-09-17 Bio-Rad Laboratories, Inc. Modified DNase compositions and methods of use thereof
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
HUE032166T2 (en) 2009-11-02 2017-09-28 Univ Washington Therapeutic nuclease preparations and methods
DK2826860T3 (da) 2010-04-23 2018-12-03 Univ Massachusetts CNS-targeting AAV-vektorer og fremgangsmåder til anvendelse deraf
EP2468870A1 (en) 2010-12-23 2012-06-27 Philip Morris Products S.A. Method for expressing desxoyribonuclease in plants
KR102428875B1 (ko) 2011-04-29 2022-08-05 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료적 뉴클레아제 조성물 및 방법
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
US10988745B2 (en) 2013-10-31 2021-04-27 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
US11225648B2 (en) * 2015-01-04 2022-01-18 Protalix Ltd. Modified DNase and uses thereof
EP3297657B1 (en) 2015-05-22 2020-03-25 GENKIN, Dmitry Dmitrievich Extracellular dna as a therapeutic target in neurodegeneration
WO2017019876A1 (en) * 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
US11578340B2 (en) 2016-10-13 2023-02-14 University Of Massachusetts AAV capsid designs
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CA3044250A1 (en) 2016-11-17 2018-05-24 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
WO2019036719A2 (en) 2017-08-18 2019-02-21 Neutrolis Therapeutics, Inc. GENETICALLY MODIFIED DNASE ENZYMES AND THEIR USE IN THERAPY
EP3740581A4 (en) 2018-01-16 2021-10-27 CLS Therapeutics Limited TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY
JP2022516635A (ja) 2019-01-04 2022-03-01 リゾルブ セラピューティクス， エルエルシー ヌクレアーゼ融合タンパク質によるシェーグレン病の処置
US20220389397A1 (en) * 2019-11-08 2022-12-08 Thermo Fisher Scientific Baltics Uab Deoxyribonuclease variants and uses thereof
EP4171614A1 (en) 2020-06-29 2023-05-03 Resolve Therapeutics, LLC Treatment of sjogren's syndrome with nuclease fusion proteins
IL301970A (en) 2020-10-07 2023-06-01 Protalix Ltd A long-acting DNase
JP2024507220A (ja) 2021-02-19 2024-02-16 セリピオン， インコーポレイテッド パラオキソナーゼ融合ポリペプチドならびに関連する組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007572A1 (en) 1988-12-23 1990-07-12 Genentech, Inc. HUMAN DNase
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
ATE155581T1 (de) 1992-11-02 1997-08-15 Genentech Inc Verdichtungsprüfung zur bewertung einer therapie für eine atmungskrankheit
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
CZ288633B6 (cs) * 1995-02-24 2001-08-15 Genentech, Inc. Na aktin rezistentní varianta lidské DNázy I a izolovaná nukleová kyselina ji kódující
SK284191B6 (sk) * 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants

Also Published As

Publication number Publication date
NZ333128A (en) 2000-08-25
CA2257133A1 (en) 1997-12-18
WO1997047751A1 (en) 1997-12-18
ATE389724T1 (de) 2008-04-15
JP2000512496A (ja) 2000-09-26
EP0910647A1 (en) 1999-04-28
US6391607B1 (en) 2002-05-21
EP0910647B1 (en) 2008-03-19
DE69738581D1 (de) 2008-04-30
AU737618B2 (en) 2001-08-23
JP3468778B2 (ja) 2003-11-17
US20080293121A1 (en) 2008-11-27
DE69738581T2 (de) 2009-04-23
ES2301180T3 (es) 2008-06-16
AU3368497A (en) 1998-01-07
CA2257133C (en) 2008-01-22
US20050170365A1 (en) 2005-08-04
PT910647E (pt) 2008-04-15
US7407785B2 (en) 2008-08-05
US20020173025A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
DK0910647T3 (da) Human DNase i hyperaktive varianter
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
ATE330967T1 (de) An her2 bindende peptidverbindungen
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DE69718734D1 (de) Bicyclische aromatische verbindungen
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
DE69529235D1 (de) Menschliche dnase i varianten
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
ATE278011T1 (de) Human dnase ii
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
TR199901385T2 (xx) Piperidin t�revleri.
MX9706429A (es) Variantes de dnasa i humana.
ATE224730T1 (de) Mittel zur behandlung von pigmentierungsstörungen
UA81601C2 (ru) Полипептид фактора vii и его применения для лечения случаев кровотечения или усиление нормальной системы кровоостановки